Adding to arsenal of movement disorder drugs approved by FDA, Neurocrine pledges to seek anxiously awaited therapies to slow progression of Huntington’s disease

Author(s)

Kenneth P. Serbin PhD, University of San DiegoFollow

Document Type

Blog Post

Publication Date

8-29-2023

Digital USD Citation

Serbin, Kenneth P. PhD, "Adding to arsenal of movement disorder drugs approved by FDA, Neurocrine pledges to seek anxiously awaited therapies to slow progression of Huntington’s disease" (2023). At Risk for Huntington's Disease. 327.
https://digital.sandiego.edu/huntingtons/327